Symbio Signs Five-Year Agreement for OmniComm’s TrialMaster
Symbio LLC, a client-focused, full-service clinical research organization, has signed a five-year contract with OmniComm Systems, Inc., a global provider of clinical data management technology. Under the agreement, Symbio will use OmniComm’s TrialMaster version 5 to develop and manage clinical study databases.
Additonally, in 2018, Symbio launched its European operations to support clients with global trials. With the opening of that division, OmniComm’s data center in Europe became a major factor in the selection of TrialMaster. Symbio cited the stability and performance of OmniComm’s EDC technology, TrialMaster’s randomization capability, and the ability to create submission-ready CRFs, ad hoc reports, and customized reports to address sponsors’ needs and requests as contributing factors to its decision.
“We are honored and thrilled that the Symbio management team has selected OmniComm’s TrialMaster platform with its advanced EDC and eSource technology to enhance the services provided to their Sponsor clients,” said Kuno van der Post, PhD, chief commercial officer, OmniComm Systems. “To have another key global CRO choose TrialMaster is very rewarding.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
